Verastem (NASDAQ:VSTM) is set to post its quarterly earnings results after the market closes on Thursday, August 1st. Analysts expect Verastem to post earnings of ($0.49) per share for the quarter.
Verastem (NASDAQ:VSTM) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.05). Verastem had a negative return on equity of 79.68% and a negative net margin of 315.21%. The business had revenue of $1.67 million for the quarter, compared to the consensus estimate of $2.84 million. On average, analysts expect Verastem to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NASDAQ VSTM traded down $0.03 during trading hours on Wednesday, reaching $1.40. 12,079 shares of the company’s stock were exchanged, compared to its average volume of 1,299,281. The business’s 50-day moving average price is $1.48. Verastem has a one year low of $1.16 and a one year high of $10.35. The company has a debt-to-equity ratio of 1.42, a current ratio of 7.57 and a quick ratio of 7.56. The firm has a market capitalization of $105.65 million, a P/E ratio of -1.03 and a beta of 2.98.
A number of analysts recently issued reports on the company. Raymond James reissued a “buy” rating on shares of Canadian Natural Resources in a research note on Friday, May 10th. HC Wainwright set a $12.00 price target on IMV and gave the stock a “buy” rating in a research report on Friday, May 10th. B. Riley reaffirmed a “buy” rating and set a $26.00 price target (up previously from $24.00) on shares of KEMET in a research report on Thursday, May 9th. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald assumed coverage on Verastem in a research report on Wednesday, April 3rd. They set an “overweight” rating and a $5.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $6.46.
Verastem Company Profile
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.